Introduction {#Sec1}
============

Extracorporeal membrane oxygenation (ECMO) is a valuable therapeutic option for patients with acute lung failure \[[@CR1]\]. During the 2009 H1N1 influenza A pandemic, the use of venovenous (VV) ECMO represented a successful rescue treatment for acute respiratory distress syndrome (ARDS) in patients failing conventional ventilation techniques \[[@CR2]\]. Due to its additional costs and the need for trained expertise, however, a rational allocation of this limited resource is of fundamental importance.

Referral and transfer of patients with H1N1-related ARDS to specialized ECMO centers have been shown to be associated with a lower risk of death compared to non-ECMO-referred patients \[[@CR3]\].

Currently, the decision to start ECMO is based on commonly used pulmonary scores assessing the severity of respiratory failure, such as Murray's acute lung injury score and the oxygenation index. A Murray score \>3 was used for enrollment and randomization in the "Conventional ventilation versus ECMO for Severe Adult Respiratory failure" (CESAR) Trial \[[@CR1]\], as it identifies severely hypoxemic patients failing protective mechanical ventilation with an estimated mortality risk higher than 50 % in comparison to conventional treatment.

Oxygenation failure, however, is rarely the direct cause of death in ECMO patients. On the contrary, a poor outcome is more likely to be determined by the presence of complications \[[@CR4]\]. Besides bleeding complications, most directly linked to the procedure itself, the most common causes of death are related to non-protective mechanical ventilation or to infectious or non-infectious inflammation \[[@CR5]\], leading to various degrees of organ dysfunction.

The aim of our study was to identify predictors of mortality in patients treated with ECMO in referral centers and to develop a score in order to better allocate resources and to define the best timing of ECMO institution.

Materials and methods {#Sec2}
=====================

Ethical aspects {#Sec3}
---------------

The present study is in compliance with the Declaration of Helsinki. In all patients ECMO was started emergently, and informed consent was waived according to Italian legislation. Individual data were anonymous according to the health ministry mandate for epidemiological and outcome surveillance of the ECMOnet program. The approval of the local ethics committees was therefore waived with no further informed consent required from the patients.

Study design {#Sec4}
------------

The data set from the ECMOnet was used to set up a prospective multicenter cohort study. The ECMOnet is a national network that includes all severely ill patients with suspected H1N1 virus infection admitted to the intensive care units (ICU) of 14 Italian tertiary care centers, endorsed and supported by the Italian Ministry of Health \[[@CR6]\]. The ECMOnet data set collected the epidemiological and clinical features, treatment data and outcomes of 60 patients with ARDS suffering from confirmed or suspected H1N1 influenza A who received ECMO according to predefined ECMOnet eligibility criteria between August 2009 and March 2010 \[[@CR6]\].

Data set {#Sec5}
--------

Baseline parameters were collected before ECMO cannulation. All patients with severe ARDS related to suspected H1N1 influenza A were included if at least one of the inclusion criteria was fulfilled despite the use of available rescue therapies: oxygenation index (OI) \> 30, PaO~2~/FiO~2~ \< 70 with PEEP ≥ 15 cmH~2~O (in patients already admitted to one of the ECMOnet centers) or PaO~2~/FiO~2~ \< 100 with PEEP ≥ 10 cmH~2~O (in patients still to be transferred), pH \< 7.25 for at least 2 h or hemodynamic instability. Exclusion criteria were intracranial bleeding or another major contraindication to anticoagulation, pre-existing severe disability and poor prognosis because of the underlying disease. Mechanical ventilation for more than 7 days was considered a relative exclusion criterion \[[@CR6]\].

Patients and procedures {#Sec6}
-----------------------

All 60 adult patients were admitted to the ICU of 1 of the 14 Italian tertiary care centers. The ECMO circuit setup consisted of a centrifugal pump and a coated polymethylpentene oxygenator. Percutaneous cannulation was performed using the Seldinger technique: 59 patients received VV ECMO (femoral-jugular in 27 cases, femoral--femoral in 26, jugular--jugular in 6); in 1 patient VV ECMO was initiated and sequentially transitioned to VA ECMO triggered by refractory hemodynamic impairment. All patients received intravenous continuous infusion of unfractionated heparin, antiviral therapy with Oseltamivir 150 mg twice a day and broad-spectrum antibiotics.

Statistical analysis {#Sec7}
--------------------

Continuous variables are reported as mean ± standard deviation or median and interquartile range, whereas categorical variables are reported as absolute numbers and percentages. Unadjusted univariate analyses were based on the Mann-Whitney U or median test and Fisher\'s exact test, respectively, with the computation of 95 % confidence intervals. For building a model predicting intrahospital mortality, multivariable analyses were performed. In detail, we modeled data using generalized estimating equations (GEE) to consider correlating features within the center, assuming the same correlation between any two elements of a cluster (exchangeable correlation matrix) \[[@CR7], [@CR8]\]. As the performance of the multivariate model depends on the initial number of variables \[[@CR9]\], we included all the variables that were statistically associated with a *p* value ≤0.25 in the univariate models. In addition, we compared models within a nested subgroup of selected variables by quasi-likelihood under the independence model criterion (QIC) \[[@CR10]\]. We started with factors revealing high significance (*p* = 0.01) in the univariate model and proceeded with forward selection. In multivariate regression, statistical significance was set at the two-tailed 0.05 level. When GEE regression coefficients could not be estimated (i.e., in case the generalized Hessian matrix was not positively definite) \[[@CR11]\], we limited the analysis to the association performed by the Fisher exact test or Mann-Whitney U test for categorical or continuous variables, respectively.

Based on the coefficients of the multivariate analysis, we combined predictors for the assessment of mortality risk in patients who presented as ECMO candidates into a new score---the ECMOnet score. With the aim to be as intuitive as possible, the score was constructed to give a result between 0 and 10. Thus, the number resulting from score calculation can be easily associated with the mortality risk. In addition, each of the five parameters is given weight by the value measured (partial score). The partial score for each parameter was established according to its frequency distribution and its weight in the final GEE model. The ECMOnet score can be calculated with the following formula where *ps* ~i~ is the partial score assigned to each parameter.$$\documentclass[12pt]{minimal}
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The goodness-of-fit of the model, plotting mortality status versus ECMOnet score, was confirmed by the GEE model and QIC statistic. Besides, c-statistics (area under ROC curve) were calculated as a measure of a model's ability to discriminate between survivors and non-survivors \[[@CR12]\]. From the ROC curve analysis, the best cutoff value was identified as the point with the highest value sensitivity and specificity (Youden index: SE + SP − 1) \[[@CR13]\]. The 95 % confidence interval for accuracy, sensitivity and specificity was calculated with normal approximation. In order to provide further external validation of the accuracy of the ECMOnet score, we used an external test set containing 74 patients suffering from ARDS because of H1N1 who received ECMO treatment in other countries \[[@CR5], [@CR14]\] or in the Italian ECMOnet centers during the 2010 H1N1 influenza A epidemics. The full data set was available for 60 patients in the validation group. Fifty-nine patients received VV ECMO, and one patient received VA ECMO. Four were converted from VV to VA ECMO because of circulatory failure during treatment \[[@CR14]\].

Two examples of the ECMOnet score calculation on paradigmatic clinical cases are also available as supplementary online material.

Statistical significance was set at the two-tailed 0.05 level for all hypothesis testing. Data were analyzed with SAS 9.2 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec8}
=======

Among the 60 patients of the 2009 H1N1 pandemic, 49 (82 %) had confirmed H1N1-associated ARDS with a survival rate of 71 %. The remaining 11 (18 %) patients without confirmed H1N1-associated ARDS presented a survival rate of 54 %. Twenty-eight patients were referred from remote hospitals to the ECMOnet referral centers and treated with ECMO.

Multiple organ failure associated with sepsis was the most common cause of death (53 %), followed by septic shock (26 %). All nonsurvivors were still on ECMO at the time of death.

As shown in Table [1](#Tab1){ref-type="table"}, all baseline characteristics, clinical parameters and vital signs were tested by univariate analysis. Using multivariate analysis, we identified five statistically significant predictors of death: bilirubin value (OR = 2.32, 95 % CI 1.52--3.52, *p* \< 0.001), systemic mean arterial pressure (OR = 0.92, 95 % CI 0.88--0.97, *p* \< 0.001), hematocrit value (OR = 0.82, 95 % CI 0.72--0.94, *p* = 0.006), preECMO hospital length of stay (OR = 1.52, 95 % CI 1.12--2.07, *p* = 0.008) and creatinine level (OR = 7.38, 95 % CI 1.43--38.11, *p* = 0.02).Table 1Patients characteristics, respiratory parameters and vital signs before ECMO initiation: comparison between surviving and nonsurviving patientsVariableTotal (*n* = 60)Alive (*n* = 41)Dead (*n* = 19)*p*Patient characteristics Age, years39.7 ± 1238 ± 12.943.3 ± 90.02 Gender (male)36 (60)26 (63.4)10 (52.6)0.6 Height (cm)168.9 ± 14.7169.2 ± 17.3168.3 ± 6.30.8 BMI (kg/m^2^)30.5 ± 8.830.7 ± 9.630.2 ± 6.90.8 BSA (m^2^)2 ± 0.42 ± 0.42 ± 0.30.6 PBW, kg62.1 ± 11.862.7 ± 13.360.7 ± 7.40.5 Weight (kg)88.3 ± 28.889.5 ± 32.285.79 ± 20.30.5 H1N1 diagnosis49 (81.7)35 (85.4)14 (73.7)0.1 PreECMO hospital stay (days)4.4 ± 6.52.6 ± 2.58.3 ± 100.006 Hospital stay (days)40.5 ± 23.943.8 ± 21.133.6 ± 28.30.3 ICU stay (days)28 ± 21.227.1 ± 17.430 ± 28.40.6 MV (h)26.9 ± 20.525.1 ± 16.230.8 ± 27.70.19 Transport on ELS28 (46.7)21 (51.2)7 (36.8)0.2 COPD7 (11.7)4 (9.8)3 (15.8)0.5 Heart disease1 (1.7)1 (2.4)0 (0)0.9 Smoke8 (13.3)7 (17.1)1 (5.3)0.2 Diabetes5 (8.3)5 (12.2)0 (0)0.2 Pregnancy4 (6.7)4 (9.8)0 (0)0.3 Neoplasia1 (1.7)1 (2.4)0 (0)0.9 Psychopathology or alcoholic patient6 (10)5 (12.2)1 (5.3)0.4Clinical parameters and vital signs Rescue therapy42 (70)29 (70.7)13 (68.4)0.8  Recruitment maneuvers41 (68.3)28 (68.3)13 (68.4)0.9  Nitric oxide10 (16.7)7 (17.1)3 (15.8)0.9  Pronation16 (26.7)12 (29.3)4 (21.1)0.6  Pulmonary vasodilator5 (8.5)2 (4.9)3 (16.7)0.2 Vasoactive amines20 (33.3)7 (17.1)13 (68.4)\<0.001 BIPAP9 (15)7 (17.1)2 (10.5)0.3 HFOV4 (6.8)2 (4.9)2 (11.1)0.4 Vasoactive and inotropic drugs37 (64.9)25 (65.8)12 (63.2)0.5 CPAP-PSV3 (5)3 (7.3)0 (0)0.5 SIMV2 (3.3)2 (4.8)0 (0)0.9 SOFA score7.8 ± 2.27 ± 2.29.32 ± 3.16\<0.001 Bilirubin (mg/dl)1.2 ± 1.20.9 ± 0.61.7 ± 1.90.02 Cardiac index (l/min/m^2^)3.7 ± 1.63.9 ± 1.93.3 ± 1.10.1 Cardiac output (l/min)7.3 ± 3.17.7 ± 3.26.6 ± 2.80.2 Creatinine (mg/dl)1.1 ± 1.10.9 ± 0.51.5 ± 1.9\<0.001 Hematocrit (%)33.4 ± 5.634.9 ± 4.730.1 ± 6.80.01 Heart rate (bpm)104 ± 21102.8 ± 21.7106.6 ± 19.70.3 Respiratory rate (bpm)26.9 ± 8.126 ± 8.728.9 ± 6.40.3 Lactates (mmol/l)2.7 ± 3.83 ± 4.52.1 ± 0.90.2 PaCO~2~ (mmHg)62.9 ± 20.163.6 ± 22.461.3 ± 14.20.6 MAP (mmHg)76.6 ± 15.779.1 ± 16.470.8 ± 12.30.007 PCV (mmHg)38 (63.3)25 (61)13 (68.4)0.6 PEEP (cmH~2~O)16 ± 3.816.4 ± 3.215.2 ± 4.90.4 pH7.3 ± 0.17.3 ± 0.17.3 ± 0.10.5 Platelet count ×103/μl191.6 ± 125.2190.4 ± 92.8194 ± 175.10.9 Peak airway pressure (cmH~2~O)34.9 ± 6.834 ± 5.937 ± 8.30.2 Plateau airway pressure (cmH~2~O)33.3 ± 4.633.9 ± 5.732.4 ± 2.20.1 Mean airway pressure (cmH~2~O)25 ± 3.4024.60 ± 3.4426.09 ± 3.280.5 CVP (mmHg)14.39 ± 4.7115.11 ± 4.0113.24 ± 5.570.2 Volume-controlled mechanical ventilation23 (38.3)15 (36.6)8 (42.1)0.7 Vt (ml)405 ± 159.4416.5 ± 171.7378.7 ± 127.40.3 Minute volume (ml)9.8 ± 4.59.9 ± 4.49.8 ± 4.60.9 Femoral vein-femoral vein configuration26 (43.3)20 (48.8)6 (31.6)0.2 Femoral vein-jugular vein configuration27 (45)18 (43.9)9 (47.4)0.8 Internal jugular vein-jugular vein configuration6 (10)3 (7.3)3 (15.8)0.3 Cannulation-related complications9 (15)4 (9.8)5 (26.3)0.05Continuous parameters presented as mean ± SD, categorical data as *n* (%)*BMI* Body max index, *BSA* body surface area, *PBW* partial weight bearing, *ECMO* extracorporeal membrane oxygenation, *ICU* intensive care unit, *MV* mechanical ventilation, *ELS* extracorporeal life support, *COPD* chronic obstructive pulmonary disease, *BIPAP* bilevel positive airway pressure, *HFOV* high-frequency oscillatory ventilation, *CPAPPSV* continuous positive airway pressure and pressure support ventilation, *CRRT* continuos renal replacement therapy, *SIMV* invasive mechanical ventilation synchronized, *SOFA* sequential organ failure assessment, *PaCO* ~*2*~ partial pressure of carbon dioxide, *MAP* mean arterial pressure, *PCV* pressure control ventilation, *PEEP* positive end expiratory pressure, *CVP* central venous pressure, *Vt* tidal volume

These five parameters were then entered into the ECMOnet score (Table [2](#Tab2){ref-type="table"}). When evaluated in the univariate GEE model, the ECMOnet score was a statistically significant predictor of mortality (OR = 3.44, 95 % CI 2.04--5.81, *p* \< 0.001). The ROC analysis further confirmed the high accuracy of the ECMOnet score (*c* = 0.857, 95 % CI 0.754--0.959, *p* \< 0.001) for the prediction of the mortality risk in patients on ECMO. An ECMOnet score of 4.5 was found to be the most appropriate cutoff for mortality risk prediction. The probability of correctly classifying patients with the ECMOnet score is 75 % (95 % CI 64--87 %). In comparison, the SOFA (*c* = 0.711, 95 % CI 0.565--0.856, *p* = 0.005) and Murray scores (*c* = 0.581, 95 % CI 0.436--0.726, *p* = 0.3) revealed a lower performance in the evaluation of pre-implant mortality risk compared to the ECMOnet score.Table 2The ECMOnet scoreParameterPartial scorePreECMO hospital length of stay (days) ≤30.5 4--71 8--111.5 \>112Bilirubin (mg/dl) ≤0.150 0.16--0.650.5 0.66--1.151 1.16--1.651.5 1.66--2.152 \>2.152.5Creatinine (mg/dl) ≤0.50 0.51--0.800.5 0.81--1.101 1.11--1.401.5 1.41--1.702 1.71--2.002.5 2.01--2.303 \>2.303.5Hematocrit (%) \>400.5 36--401 31--351.5 ≤302.0Mean arterial pressure (mmHg) \>900 61--900.5 ≤601*ECMO* Extracorporeal memabrane oxygenation

We further analyzed the performance of the ECMOnet score to the subgroups of patients referred or not referred from remote hospitals. Not only was the prediction of mortality risk excellent in the 49 patients with H1N1 infection (*c* = 0.905, 95 % CI 0.820--0.991, *p* \< 0.001), but also the ECMOnet score performed well in both groups of patients (*n* = 28), referred (*c* = 0.833, 95 % CI 0.630--0.999, *p* = 0.001) or not referred (*n* = 32) from remote hospitals (*c* = 0.838, 95 % CI 0.693--0.984, *p* \< 0.001).Furthermore, we examined the reliability of the ECMOnet score by an external validation analysis: the validation group consisted of 74 patients with ARDS (45 male and 29 female), of whom 81 % (60/74) had confirmed H1N1 infection, and 57 % (42/74) were transferred from remote hospitals to the tertiary referral centers after the initiation of treatment with extracorporeal support. Mean age was 45 ± 14 years; overall survival rate was 49 % (36/74).The ROC analysis (Fig. [1](#Fig1){ref-type="fig"}) of this external test set revealed a strong capacity of the ECMOnet score to distinguish survivors from nonsurvivors (*c* = 0.694, 95 % CI 0.562--0.826, *p* = 0.004). The accuracy was 62 % (95 % IC 49--74 %), and sensitivity and specificity were 51 % (95 % IC 35--68 %) and 76 % (95 % IC 59--93 %), respectively.Fig. 1ROC curve of the ECMOnet score in the external validation test set

Discussion {#Sec9}
==========

This study shows that mortality of adult patients suffering from influenza A (H1N1)-related ARDS undergoing VV ECMO is related to extrapulmonary organ function at the time of cannulation. PreECMO hospital length of stay; creatinine, bilirubin and hematocrit values; and systemic mean arterial pressure were significantly associated with mortality as assessed by multivariate analysis, while respiratory parameters were not associated with survival. To improve risk stratification and prediction of mortality risk at the time of VV ECMO initiation, we developed a multifactorial scoring system---the ECMOnet score.

Up to now, most data explaining the rates and causes of death refer to the time point after the start of ECMO: in a large multicenter database of 1,473 adult patients supported with ECMO for respiratory failure, survival at hospital discharge was 50 % \[[@CR4]\]. Non-survivors displayed a higher rate of complications, including mechanical circuit complications; renal complications; surgical, GI and pulmonary hemorrhages; hyperglycemia, infections, arrhythmias and pneumothorax \[[@CR4]\]. In a population of 137 pediatric patients undergoing VA ECMO, Morris and colleagues found that the development of renal and hepatic dysfunction during ECMO predicted mortality in postoperative patients with statistical significance \[[@CR15]\]. Recently, Smalley et al. \[[@CR16]\] performed a retrospective study on 50 children with pneumonia and managed with ECMO. In their study, the need to change the ECMO circuit and the need for continuous renal replacement therapy were predictors of death. Wagner et al. \[[@CR17]\] found that, among 26 risk factors analyzed in a total of 72 patients receiving pulmonary ECMO, only preECMO serum creatinine levels correlated with survival. This result is in line with our findings, even if in their study adults, children and neonates suffering from different pulmonary diseases and treated with either VV or VA ECMO were all analyzed as a unique study group.

However, studies on this topic are few and potentially biased by the multiple etiologies of respiratory failure. In contrast, our patients presented as an homogeneous population with H1N1-associated pneumonia (confirmed in 81.7 %) referred to tertiary ECMO centers.

Furthermore, patients enrolled in our study were stringently treated with VV ECMO according to a national protocol with definite inclusion and exclusion criteria. Accordingly patient management was similar in the 14 tertiary centers, as the ECMOnet organized multiple ECMO training courses open to physicians, perfusionists and nurses \[[@CR18]\]. The parameters identified in our study are very simple to implement clinically, and the use of the ECMOnet score for the evaluation of critically ill patients for VV ECMO institution can be applied easily to patients referred from remote hospitals. External validation indicates that the information provided by the ECMOnet score is statistically robust in further patient groups.

The potential benefits of the new score, however, may be not limited to the setting of H1N1 influenza A virus-related acute lung failure. After further validation in different settings of acute respiratory distress syndrome, endorsing this score in clinical practice would allow cannulation of patients in the presence of organ dysfunction before strict respiratory criteria are met and refusal of ECMO in patients with high predicted mortality.

Protective ventilation was shown to improve survival in patients with ARDS by the ARDS network \[[@CR19]\]. Besides its lung-protective effects, the favorable effects of ECMO appear to be related to its beneficial hemodynamic impact on preserving distal perfusion (i.e., kidney, liver), particularly if focusing on causes of death.

ECMO is safer, cheaper and simpler than in previous eras \[[@CR20]\]. While the CESAR trial showed an improvement in survival \[[@CR1]\], the ECMOnet experience demonstrated that its application is feasible and effective \[[@CR6]\]. Moreover, the ECMOnet data set analysis allowed the development of the ECMOnet score, and the validation analysis revealed a potentially strong impact on clinical practice.

Some limitations of this study should be acknowledged. First, complications occurring during ECMO have a strong impact on the outcome, and these are not addressed with baseline parameters. Our study used predefined indications for ECMO based on gas exchange and ventilator pressure, which are not universally standardized and remain an important matter of discussion. Another limitation is the inability to provide a distinction between patients with viral sepsis at baseline and those who had superinfection, as the majority of deaths in our population were related to multiple organ failure associated with sepsis and septic shock. However, the facts should not be underestimated that the overlap between shock, SIRS, ECMO itself and sepsis is always part of the clinical scenario in patients undergoing extracorporeal support \[[@CR21]\] and that all patients were already septic at baseline. Finally, the accuracy of the ECMOnet score \[62 % (95 % IC 49--74 %)\], and the sensitivity and specificity \[51 % (95 % IC 35--68 %) and 76 % (95 % IC 59--93 %), respectively\] should be further validated in larger ARDS populations.

Conclusions {#Sec10}
===========

Our data provide new perspectives concerning the allocation of resources for VV ECMO. We confirm the strong clinical perception that survival is strongly correlated to extrapulmonary organ function at the time of ECMO initiation. This knowledge may help to identify potential candidates for ECMO support according to their mortality risk and provides guidance to solve crucial economic and ethical issues.
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